IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...
Shanghai Unveils Policies to Boost Global Biomedical R&D Hub
The Shanghai municipal government has released a set of policies and measures aimed at accelerating...
WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...
Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...
Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...
Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...
JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...
Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...
Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...
Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...
IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD
China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...
ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development
Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of...
Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...
China’s CDE, HNMPA, and Bo’ao Lecheng Release Real-world Drug Research Measures
The Center for Drug Evaluation (CDE), Hainan Medical Products Administration (HNMPA), and Bo’Ao Lecheng Medical...
Hotgen Biotech Receives FDA EUA for COVID-19 Antigen Home Test
China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving Emergency Use Authorization (EUA) from...
Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis
Holland-based information and software solutions provider Wolters Kluwer has announced a partnership with China’s National...
Jiangxi Healthcare Security Administration Launches New VBP Tender
The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...
Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem
China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...